Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) Tetramer Protein
Catalog No: NYESO1-HP008
- Species
- Human
- Expression System
- HEK293
- Tag
- His, Avi
- Activity
- Activity verified
Product overview
Recombinant Human NY-ESO-1(HLA-A*02:01) Tetramer Protein is expressed from HEK293 with His tag and Avi tag at the C-terminus,tetramer is assembled by biotinylated monomer and streptavidin. It contains Gly25-Thr305(HLA-A*02:01), Ile21-Met119(B2M) and SLLMWITQV peptide (accession: A0A140T913(HLA-A*02:01) & P61769(B2M) &SLLMWITQV).
Product Details
- Molecular Aliases
- MHC; MY-ESO-1; CT6.1; LAGE-2; CTAG1; CTAG1B; ESO1CTAG; LAGE2A; NY-ESO-1; CTAG1A
- Protein Length
- Gly25-Thr305
- Expression System
- HEK293
- Theoretical Molecular Weight
- The protein has a predicted MW of 258 kDa. Due to glycosylation, the protein migrates to 260-265 kDa under Non reduced (N) condition based on Bis-Tris PAGE result.
- Purity
- > 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
- Endotoxin
- Less than 1 EU per μg by the LAL method.
- Buffer / Formulation
- Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
- State
- Lyophilized
- Storage Conditions
- -20 to -80°C for 24 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
- Reconstitution Advice
- Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.
Data Display
Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) Tetramer on Bis-Tris PAGE under Non reduced (N) condition. The purity is greater than 95%.
The purity of Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) Tetramer is greater than 95% as determined by SEC-HPLC.
Immobilized Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) Tetramer, His Tag at 5μg/ml (100μl/well) on the plate. Dose response curve for Anti-HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) Antibody, hFc Tag with the EC50 of 1.0ng/ml determined by ELISA.
Background
NY-ESO-1 or New York esophageal squamous cell carcinoma 1 is a well-known cancer-testis antigen (CTAs) with re-expression in numerous cancer types. Its ability to elicit spontaneous humoral and cellular immune responses, together with its restricted expression pattern, have rendered it a good candidate target for cancer immunotherapy.
References
- (1)Thomas R, Al-Khadairi G, Roelands J, Hendrickx W, Dermime S, Bedognetti D, Decock J. NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives. Front Immunol. 2018 May 1;9:947. doi: 10.3389/fimmu.2018.00947. PMID: 29770138; PMCID: PMC5941317.
Have questions about this product?
Our technical team can help with product selection, application questions and order support.